You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 4,197,238

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,197,238

Title:	Method of preparation of human albumin using polyethylene glycol
Abstract:	Human albumin free of a blood group substance can simply be prepared by treating an albumin fraction, especially from human placenta with polyethylene glycol to precipitate contaminant proteins containing the blood group substance and recovering albumin from the supernatant fluid.
Inventor(s):	Murata; Yorihiko (Amagasaki, JP), Tsutsui; Eizo (Hirakata, JP)
Assignee:	The Green Cross Corporation (Osaka, JP)
Application Number:	05/935,843
Patent Claims:	1. A method for removing a blood group substance from an aqueous solution of human albumin, said method comprising treating an aqueous solution of albumin of human origin free from gamma-globulin and containing a blood-group substance and hypotensive substance with polyethylene glycol at pH of 6.6 to 8.0 the effective polyethylene glycol concentration in the aqueous albumin solution of 13 to 20% (w/v) in the presence of an inorganic salt at a concentration of at most 50 g/liter measured as sodium chloride and at a temperature in the range of 2.degree. C. to 30.degree. C., the resulting polyethylene glycol/albumin solution having a protein concentration of 5 to 40 g/liter, thereby precipitating and removing contaminant proteins containing said blood-group substance and recovering albumin from the supernatant fluid. 2. A method according to claim 1 wherein the aqueous solution of albumin contains at leat 50% of albumin based on the total protein and the aqueous solution of albumin is originated from human placenta or human retroplacental blood and the polyethylene glycol has an average molecular weight of 2,000 to 10,000. 3. A method according to claim 1 including the steps of adjusting the supernatant fluid to a pH of 4.5 to 5.6 and to a polyethylene glycol concentration of 20 to 30% (w/v) to precipitate albumin and then recovering albumin therefrom. 4. A method according to claim 3 wherein the original aqueous solution of albumin contains at least 50% of albumin based on the total protein and the aqueous solution of albumin is originated from human placenta or human retroplacental blood and the polyethylene glycol has an average molecular weight of 2,000 to 10,000. 5. A method for removing a blood group substance from an aqueous solution of human albumin, said method comprising treating an aqueous solution of albumin of human origin free from gamma-globulin and containing a blood-group substance and hypotensive substance with polyethylene glycol at pH of 8.0 to 9.6, the effective polyethylene glycol concentration in the aqueous albumin solution of 15 to 30% (w/v), in the presence of an inorganic salt at a concentration of at most 50 g/liter measured as sodium chloride and at a temperature in the range of 2.degree. C. to 30.degree. C. the resulting polyethylene glycol/albumin solution having a protein concentration of 5 to 40 g/liter, thereby precipitating and removing contaminant proteins containing said blood-group substance and recovering albumin from the supernatant fluid. 6. A method according to claim 5 wherein the aqueous solution of albumin contains at least 50% of albumin based on the total protein and the aqueous solution of albumin is originated from human placenta or human retroplacental blood and the polyethylene glycol has an average molecular weight of 2,000 to 10,000. 7. A method according to claim 5 including the steps of adjusting the supernatant fluid to a pH of 4.5 to 5.6 and to a polyethylene glycol concentration of 20 to 30% (w/v) to precipitate albumin and then recovering albumin therefrom. 8. A method according to claim 7 wherein the original aqueous solution of albumin contains at least 50% of albumin based on the total protein and the aqueous solution of albumin is originated from human placenta or human retroplacental blood and the polyethylene glycol has an average molecular weight of 2,000 to 10,000. 9. A method for removing a blood group substance from an aqueous solution of human albumin containing at least 50% of the albumin, based on the total protein, the aqueous solution originating from human placenta or human retroplacental blood, said method comprising (1) treating an aqueous solution of albumin of human origin containing a blood-group substance free from gamma-globulin, and hypotensive substance with polyethylene glycol having an average molecular weight in the range of 2,000 to 10,000 and at pH of 6.6 to 9.6 at a polyethylene glycol concentration of 13 to 30% (w/v) to the aqueous solution of albumin having a protein concentration of 5 to 40 g/liter, an inorganic salt concentration of at most 50 g/liter, measured as sodium chloride, and at a temperature in the range of 2.degree. C. to 30.degree. C.; and (2) precipitating and substantially removing contaminant proteins containing said blood-group substance and said hypotensive substance and (3) recovering human albumin from the supernatant fluid. 10. A method according to claim 1, wherein the aqueous solution of albumin is originated from human placenta or human retroplacental blood. 11. A method according to claim 1, wherein the aqueous solution of albumin contains at least 50% of albumin on the total protein contained. 12. A method according to claim 1, wherein the polyethylene glycol has an average molecular weight of 2,000 to 10,000.

Details for Patent 4,197,238

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942	⤷ Try a Trial	1997-04-12
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954	⤷ Try a Trial	1997-04-12
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976	⤷ Try a Trial	1997-04-12
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978	⤷ Try a Trial	1997-04-12
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995	⤷ Try a Trial	1997-04-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.